Pancreatic Cancer Research

ResearcherInsermNo recent work listed

Julien Edeline

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8289-7741; OpenAlex author ID A5069522018. Sources: ClinicalTrials.gov.

Their work

Papers
6
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2017: 1 paper, 1 trial · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers

Papers 6

  1. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  2. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  3. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Co-author DOI 10.1177/17588359211029825↗
  4. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗
  5. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  6. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Co-author DOI 10.1016/j.dld.2017.02.007↗

Trials 1

  1. Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer Principal investigator NCT02921646↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Astrid Lièvre · 6 shared papers, 2017–2022 · strength 0.62
  2. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  3. Édouard Auclin · 2 shared papers, 2022 · strength 0.26
  4. Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
  5. Dominique Béchade · 2 shared papers, 2022 · strength 0.26
  6. Julien Taı̈eb · 2 shared papers, 2022 · strength 0.26
  7. Simon Pernot · 2 shared papers, 2022 · strength 0.26
  8. Marine Gilabert · 2 shared papers, 2022 · strength 0.26
  9. David Tougeron · 2 shared papers, 2022 · strength 0.26
  10. Anthony Turpin · 2 shared papers, 2020–2021 · strength 0.22
  11. Déwi Vernerey · 2 shared papers, 2019–2020 · strength 0.17
  12. Cindy Neuzillet · 2 shared papers, 2019–2020 · strength 0.17
  13. Angélique Vienot · 2 shared papers, 2019–2020 · strength 0.17
  14. A Váry · 1 shared paper, 2021 · strength 0.12
  15. Frédéric Di Fiore · 1 shared paper, 2021 · strength 0.12
  16. Charlotte Peugniez · 1 shared paper, 2020 · strength 0.10
  17. Christophe Borg · 1 shared paper, 2020 · strength 0.10
  18. Hortense Chevalier · 1 shared paper, 2020 · strength 0.10
  19. Pascal R. Hammel · 1 shared paper, 2020 · strength 0.10
  20. Francesco Leone · 1 shared paper, 2019 · strength 0.07
  21. Pasquale Lombardi · 1 shared paper, 2019 · strength 0.07
  22. Caterina Vivaldi · 1 shared paper, 2019 · strength 0.07
  23. Massimo Aglietta · 1 shared paper, 2019 · strength 0.07
  24. Alessandro Passardi · 1 shared paper, 2019 · strength 0.07
  25. Rosella Spadi · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.